IP Library Granted Patent US 7,351,745
Granted Patent B2
US 7,351,745 · App. 11/021,242 · Granted Apr 1, 2008

Compositions and methods of their use for improving the condition and appearance of skin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,351,745
App. No.
11/021,242
Granted
Apr 1, 2008
Kind
B2
Abstract

The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and/or aesthetic appearance of skin.

Claims (17)

1. A method of ameliorating, reducing, or treating progressive degradation of a dermal-epidermal junction and/or degradation of a cell-cell cohesion in skin, comprising topicafly applying to skin a topical composition comprising:

(a) a cosmetically, dermatologically, pharmaceutically, or physiologically effective amount of an active agent, wherein said active agent is S-Methyl-L-Cysteine and S-Phenyl-L-Cysteine sufficient to increase expression levels of at least one gene selected from the group consisting of: Beta-catenin, Collagen 4, Collagen 7, Frizzled 10, Estrogen Receptor alpha, Hyaluronic acid synthase, and combinations thereof; and

(b) a cosmetically, dermatologically, pharmaceutically, or physiologically acceptable vehicle, in an amount effective to ameliorate, reduce, or treat progressive degradation of a dermal-epidermal junction and/or degradation of a cell-cell cohesion in skin, wherein the progressive degradation of a dermal-epidermal junction and/or degradation of a cell-cell cohesion in skin is not hyperkeratosis.

2. The method of claim 1 , wherein said composition is applied for a period of time sufficient to ameliorate, reduce, or treat progressive degradation of a dermal-epidermal junction and/or degradation of a cell-cell cohesion in skin.

3. The method of claim 1 , wherein said applying of the composition occurs at least once daily for a period of time sufficient to, ameliorate, reduce, or treat progressive degradation of a dermal-epidermal junction and/or degradation of a cell-cell cohesion in skin.

4. The method of claim 1 , wherein the active agent is present in an amount effective to improve the condition and/or aesthetic appearance of skin.

5. The method of claim 1 , wherein the active agent is present in an amount from about 0.0001 weight % to about 20 weight %, based upon the total weight of the composition.

6. The method of claim 1 , wherein the active agent is present in an amount from about 0.001 weight % to about 10 weight %, based upon the total weight of the composition.

7. The method of claim 4 , wherein the improvement in the condition and/or aesthetic appearance is selected from the group consisting of: reducing dermatological signs of chronological aging, photo-aging, hormonal aging, and/or actinic aging; reducing the appearance of lines and/or wrinkles; reducing the noticeability of facial lines and wrinkles, facial wrinkles on the cheeks, forehead, perpendicular wrinkles between the eyes, horizontal wrinkles above the eyes, and around the mouth, marionette lines, and particularly deep wrinkles or creases; reducing and/or diminishing the appearance and/or depth of lines and/or wrinkles; improving the appearance of suborbital lines and/or periorbital lines, reducing the appearance of crow's feet; rejuvenating and/or revitalizing skin, particularly aging skin; reducing skin fragility; and/or reversing of loss of glycosaminoglycans and/or collagen; ameliorating the effects of estrogen imbalance; skin atrophy; reducing, and/or treating hyperpigmentation; minimizing skin discoloration; improving skin tone, radiance, clarity and/or tautness; reducing and/or ameliorating skin sagging; improving skin firmness, plumpness, suppleness and/or softness; improving procollagen and/or collagen production; improving skin texture and/or promoting retexturization; improving skin barrier repair and/or function, improving the appearance of skin contours; restoring skin luster and/or brightness; minimizing dermatological signs of fatigue and/or stress; resisting environmental stress; replenishing ingredients in the skin decreased by aging and/or menopause; improving communication among skin cells; increasing cell proliferation and/or multiplication; increasing skin cell metabolism decreased by aging and/or menopause; retarding cellular aging; improving skin moisturization; enhancing skin thickness; increasing skin elasticity and/or resiliency; enhancing exfoliation; improving microcirculation; decreasing cellulite formation; and any combinations thereof.

8. A method of improving the condition and/or aesthetic appearance of skin comprising topically applying to skin a topical composition comprising;

(a) a cosmetically, dermatologically, pharmaceutically, or physiologically effective amount of an active agent, wherein said active agent is S-Methyl-L-Cysteine and S-Phenyl-Cysteine sufficient to increase expression levels of at least one gene selected from the group consisting of Beta-catenin, Collagen 4, Collagen 7, Frizzled 10, Estrogen Receptor alpha, Hyaluronic acid synthase, and combinations thereof; and

(b) a cosmetically, dermatologically, pharmaceutically, or physiologically acceptable vehicle, in an amount effective to improve the condition and/or aesthetic appearance of skin, wherein the condition is not hyperkeratosis.

9. The method of claim 8 , wherein said composition is applied for a period of time sufficient to improve the condition and/or aesthetic appearance of skin.

10. The method of claim 8 , wherein said applying of the composition occurs at least once daily for a period of time sufficient to improve the condition and/or aesthetic appearance of skin.

11. The method of claim 8 , wherein the active agent is present in an amount from about 0.0001 weight % to about 20 weight %, based upon the total weight of the composition.

12. The method of claim 8 , wherein the active agent is present in an amount from about 0.001 weight % to about 10 weight %, based upon the total weight of the composition.

13. The method of claim 8 , wherein the improvement in the condition and/or aesthetic appearance is selected from the group consisting of; reducing dermatological signs of chronological aging, photo-aging, hormonal aging, and/or actinic aging; reducing the appearance of lines and/or wrinkles; reducing the noticeability of facial lines and wrinkles, facial wrinkles on the cheeks, forehead, perpendicular wrinkles between the eyes, horizontal wrinkles above the eyes, and around the mouth, marionette lines, and particulary deep wrinkles or creases; reducing and/or diminishing the appearance and/or depth of lines and/or wrinkles; improving the appearance of suborbital lines and/or periorbital lines, reducing the appearance of crow's feet; rejuvenating and/or revitalizing skin, particularly aging skin; reducing skin fragility; reversing of loss of glycosaminoglycans and/or collagen; ameliorating the effects of estrogen imbalance, reducing skin atrophy reducing and/or treating hyperpigmentation; minimizing skin discoloration, improving skin tone, radiance, clarity and/or tautness; reducing and/or ameliorating skin sagging; improving skin firmness, plumpness, suppleness and/or softness; improving procollagen and/or collagen production; improving skin texture and/or promoting retexturization; improving skin barrier repair and/or function; improving the appearance of skin contours; restoring skin luster and/or brightness, minimizing dermatological signs of fatigue and/or stress; resisting environmental stress, replenishing ingredients in the skin decreased by aging and/or menopause; improving communication among skin cells; increasing cell proliferation and/or multiplication; increasing skin cell metabolism decreased by aging and/or menopause; retarding cellular aging; improving skin moisturization; enhancing skin thickness; increasing skin elasticity and/or resiliency; enhancing exfoliation; improving microcirculation; decreasing cellulite formation; and any combinations thereof.

Assignments (4)
SECURITY INTEREST Recorded Nov 14, 2019
From: AVON PRODUCTS, INC.
To: CITIBANK, N.A., LONDON BRANCH
Reel/Frame 051032/0210 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Aug 15, 2016
From: CITIBANK, N.A.
To: AVON PRODUCTS, INC.
Reel/Frame 039690/0331 →
SECURITY INTEREST Recorded Jun 12, 2015
From: AVON PRODUCTS, INC.
To: CITIBANK, N.A.
Reel/Frame 035899/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2005
From: DRYER, LAURENCE; PTCHELINTSEV, DMITRI
To: AVON PRODUCTS, INC.
Reel/Frame 016863/0071 →